Deep sea creatures provide a guiding light in the quest to develop cancer therapies

January 9, 2018, University of Southern California
Electron microscopic image of a single human lymphocyte. Credit: Dr. Triche National Cancer Institute

A team of scientists at the Keck School of Medicine of USC is looking to some deep sea dwellers to create a better way to develop cancer-fighting therapies. Harnessing the power of the enzymes that give these marine animals the ability to glow, the team created a test that makes it easy for researchers to see whether a therapy is having its intended effect—killing cancer cells. The results of their study were published in Scientific Reports on Jan. 9, 2018.

"One of the most promising areas in research is immunotherapy, including chimeric antigen receptor-T (CAR-T) cells. It is also one of the most difficult because the methods for testing immunotherapies are not ideal," says corresponding author Preet M. Chaudhary, MD, PhD, professor of medicine at the Keck School, chief of the division of hematology and center for blood diseases, and director for bone marrow transplant at USC Norris Comprehensive Cancer Center. "Radioactive chromium release assay is the gold standard for testing whether an immunotherapy kills . This method is expensive, complicated and requires special disposal practices. Other available methods also suffer from limitations and don't allow scientists to rapidly screen immunotherapeutic agents to find the best candidates."

The team set out to develop a simple, precise and inexpensive test based on marine animal luciferases, the enzymes responsible for bioluminescence. A group of small crustaceans and deep sea shrimp were selected for their bright bioluminescence, and their luciferases became the basis of the test, called the Matador assay. Engineered to get trapped inside cells, the luciferases leak out of cells when they die, causing a visible glow. The level of luminescence can then be measured with a luminometer.

To test the Matador assay's effectiveness at measuring cell death, several different types of cancer cells, including chronic myelogenous leukemia, , Burkitt's lymphoma and solid tumors, were treated with a variety of immunotherapies, including CAR-T cells, bispecific T-cell engagers and monoclonal antibodies. Results showed that the assay was so sensitive that it could detect the death of a single cell, a level of sensitivity far exceeding existing assays. Chaudhary's lab has since developed more than 75 cancer cell lines expressing the marine luciferases and used them successfully in the Matador assay to develop next-generation CAR-T cells.

The assay is fast, inexpensive and can be performed in a 384-well plate format, saving time and reagents.

"In our hands, the Matador assay can detect cell death in as little as 30 minutes, which can ultimately translate to more expedient treatments for patients getting cellular immunotherapies such as CAR-T ," Chaudhary says.

The Matador assay has many potential applications in biomedical research and cellular therapy manufacturing, he explains.

"It could potentially play a role in screening other types of anticancer agents or even measuring environmental toxins."

Explore further: Assay to ID anticancer reagents targeting fructose-1,6-bisphosphate aldolase

More information: Hittu Matta et al, Development and characterization of a novel luciferase based cytotoxicity assay, Scientific Reports (2018). DOI: 10.1038/s41598-017-18606-1

Related Stories

Assay to ID anticancer reagents targeting fructose-1,6-bisphosphate aldolase

December 21, 2017
An original research report by Eun Jeong Cho et al. (University of Texas at Austin) in the January 2018 Issue of SLAS Discovery presents a newly designed biochemical assay that is rapid, sensitive, inexpensive, and high-throughput ...

A rapid alternative to standard safety tests for lentiviral vectors

September 21, 2017
A new, publicly available test to assess the safety of cell therapy products altered by lentivirus generates results within a few hours, potentially hastening the pace at which viral immunotherapies move into clinical trial. ...

Technique identifies chemotherapy-resistant cells within acute myeloid leukemia tumors

September 6, 2016
Although chemotherapy can sometimes cure acute myeloid leukemia and other hematologic cancers, many patients experience relapses when their tumors become resistant to available chemotherapies. This resistance may be caused ...

Genome editing enhances T-cells for cancer immunotherapy

November 20, 2017
Researchers at Cardiff University have found a way to boost the cancer-destroying ability of the immune system's T-cells, offering new hope in the fight against a wide range of cancers.

Vorinostat renders dormant HIV infection vulnerable to clearance

August 1, 2017
The ability for HIV to hide in the body in a dormant state makes curing the 40 million people living with the virus a challenge. Researchers at the University of North Carolina at Chapel Hill have shown the drug Vorinostat ...

The IASLC Atlas of PD-L1 Immunohistochemistry (IHC) Testing in Lung Cancer released

May 3, 2017
Media Contact: Becky Bunn, MSc Public Relations ManagerBecky.Bunn@IASLC.org | 720-325-2946

Recommended for you

Daily low-dose aspirin may be weapon against ovarian cancer

July 20, 2018
(HealthDay)— One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest.

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.